Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

NASDAQ:SKIN - Nasdaq - US88331L1089 - Common Stock - Currency: USD

1.61  +0.01 (+0.63%)

After market: 1.66 +0.05 (+3.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SKIN. SKIN was compared to 37 industry peers in the Personal Care Products industry. SKIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SKIN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SKIN had negative earnings in the past year.
SKIN had a negative operating cash flow in the past year.
In the past 5 years SKIN reported 4 times negative net income.
SKIN had negative operating cash flow in 4 of the past 5 years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

SKIN's Return On Assets of -4.03% is on the low side compared to the rest of the industry. SKIN is outperformed by 63.89% of its industry peers.
The Return On Equity of SKIN (-47.17%) is worse than 69.44% of its industry peers.
Industry RankSector Rank
ROA -4.03%
ROE -47.17%
ROIC N/A
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

SKIN has a Gross Margin of 61.43%. This is comparable to the rest of the industry: SKIN outperforms 50.00% of its industry peers.
SKIN's Gross Margin has declined in the last couple of years.
SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SKIN has been reduced compared to 1 year ago.
The debt/assets ratio for SKIN is higher compared to a year ago.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

SKIN has an Altman-Z score of 0.20. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
SKIN has a worse Altman-Z score (0.20) than 77.78% of its industry peers.
SKIN has a Debt/Equity ratio of 9.23. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 9.23, SKIN is doing worse than 91.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 9.23
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC6.27%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.56 indicates that SKIN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.56, SKIN belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
A Quick Ratio of 5.57 indicates that SKIN has no problem at all paying its short term obligations.
SKIN's Quick ratio of 5.57 is amongst the best of the industry. SKIN outperforms 94.44% of its industry peers.
Industry RankSector Rank
Current Ratio 6.56
Quick Ratio 5.57
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SKIN have decreased strongly by -160.36% in the last year.
Looking at the last year, SKIN shows a very negative growth in Revenue. The Revenue has decreased by -12.94% in the last year.
SKIN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.50% yearly.
EPS 1Y (TTM)-160.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-19.1%

3.2 Future

Based on estimates for the next years, SKIN will show a very negative growth in Earnings Per Share. The EPS will decrease by -47.48% on average per year.
The Revenue is expected to grow by 6.87% on average over the next years.
EPS Next Y-259.37%
EPS Next 2Y-92.35%
EPS Next 3Y-47.48%
EPS Next 5YN/A
Revenue Next Year-15.56%
Revenue Next 2Y-7.29%
Revenue Next 3Y-1.14%
Revenue Next 5Y6.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as SKIN's earnings are expected to decrease with -47.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-92.35%
EPS Next 3Y-47.48%

More info and screens

0

5. Dividend

5.1 Amount

SKIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (2/21/2025, 8:00:02 PM)

After market: 1.66 +0.05 (+3.11%)

1.61

+0.01 (+0.63%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners86.75%
Inst Owner Change-94.26%
Ins Owners8.64%
Ins Owner Change-0.1%
Market Cap199.83M
Analysts49.33
Price Target1.75 (8.7%)
Short Float %7.83%
Short Ratio16.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.39%
Min EPS beat(2)20.82%
Max EPS beat(2)101.96%
EPS beat(4)4
Avg EPS beat(4)56.19%
Min EPS beat(4)9.17%
Max EPS beat(4)101.96%
EPS beat(8)7
Avg EPS beat(8)49.55%
EPS beat(12)10
Avg EPS beat(12)542.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.67%
Min Revenue beat(2)-9.83%
Max Revenue beat(2)4.5%
Revenue beat(4)2
Avg Revenue beat(4)0.52%
Min Revenue beat(4)-9.83%
Max Revenue beat(4)8.3%
Revenue beat(8)3
Avg Revenue beat(8)-2.65%
Revenue beat(12)7
Avg Revenue beat(12)2.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.46%
PT rev (3m)-21.46%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)1.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS2.8
BVpS0.48
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.03%
ROE -47.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.43%
FCFM N/A
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 9.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.49%
Cap/Sales 2.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.56
Quick Ratio 5.57
Altman-Z 0.2
F-Score5
WACC6.27%
ROIC/WACCN/A
Cap/Depr(3y)59.93%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
EPS Next Y-259.37%
EPS Next 2Y-92.35%
EPS Next 3Y-47.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-19.1%
Revenue Next Year-15.56%
Revenue Next 2Y-7.29%
Revenue Next 3Y-1.14%
Revenue Next 5Y6.87%
EBIT growth 1Y64.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.6%
EBIT Next 3Y38.55%
EBIT Next 5Y32.29%
FCF growth 1Y88.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.38%
OCF growth 3YN/A
OCF growth 5YN/A